{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:15:23Z","timestamp":1768515323806,"version":"3.49.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","award":["2018SK52604"],"award-info":[{"award-number":["2018SK52604"]}],"id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> 5-fluorouracil (5-FU) is basically used in the field of postoperative chemotherapy of gastric cancer (GC), the goal of this study was to evaluate improvement of long-term survival rate among GC patients after the 5-FU implants treatment.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The study included 145 patients with gastric cancer who received postoperative chemotherapy with 5-FU implants and had complete follow-up information. According to the sex, age and clinical stage of 5-FU implants group, 74 patients were matched as the control group at the same time. In the study, we compared the 5-year overall survival rate with progression-free survival rate in the two groups, and the drug safety for both groups during the treatment was also compared.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The median follow-up time was 85\u00a0months (range 60\u2013116\u00a0months). 31 patients (21.38%) died of tumor recurrence in 5-FU implants group and 21 (28.38%) in control group. In the control group, metastatic lesions were found in the small intestine, left adrenal gland and peritoneum in three patients. The 5-year progression-free survival (PFS) rate was 79.71% in 5-FU group and 67.12% in control (<jats:italic>p<\/jats:italic> = 0.0045). The 5-year overall survival (OS) rate was 77.68% in 5-FU implants group and 64.87% in control (<jats:italic>p<\/jats:italic> = 0.0159). Both the 5-years OS and PFS rates in 5-FU group were better than control group without significant side effect.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> 5-FU implants may improve 5-years OS and PFS rates after surgery in gastric cancer patients, while good safety profile suggests it could be reliable.<\/jats:p>","DOI":"10.3389\/fphar.2021.659258","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:28:32Z","timestamp":1618295312000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Retrospective Cohort Study of Intraoperative Administration of Sustained-Release 5-Fluorouracil Implants in Advanced Gastric Cancer Patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Jie","family":"Ge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianxiang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samim","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.6004\/jnccn.2016.0137","article-title":"Gastric cancer, version 3.2016, NCCN clinical practice guidelines in Oncology","volume":"14","author":"Ajani","year":"2016","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/s0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/s0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"The Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/annonc\/mdi270","article-title":"Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801)","volume":"16","author":"Bouch\u00e9","year":"2005","journal-title":"Ann. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"","journal-title":"CA: A Cancer J. Clinicians"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3390\/jcm8101685","article-title":"Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer-A systematic review","volume":"8","author":"Brenkman","year":"2019","journal-title":"Jcm"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s10120-018-0831-0","article-title":"Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis","volume":"21","author":"Cai","year":"2018","journal-title":"Gastric Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/annonc\/mdf302","article-title":"A phase III randomized trial of 5-fluorouracil, doxorubicin,and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer","volume":"13","author":"Chang","year":"2002","journal-title":"Ann. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/02724980443000863","article-title":"Comparative proteomics of apoptosis initiation induced by 5-fluorouracil in human gastric cancer","volume":"49","author":"Chen","year":"2006","journal-title":"Chin. J. Physiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/0394632016648176","article-title":"Safety of implanting sustained-release 5-fluorouracil into hepatic cross-section and omentum majus after primary liver cancer resection","volume":"29","author":"Chen","year":"2016","journal-title":"Int. J. Immunopathol Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/10837450.2013.769568","article-title":"In vitroandin vivoevaluation of injectable implants for intratumoral delivery of 5-fluorouracil","volume":"19","author":"Chen","year":"2014","journal-title":"Pharm. Dev. Technol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.3390\/md11093517","article-title":"Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo","volume":"11","author":"Cheng","year":"2013","journal-title":"Mar. Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1245\/s10434-015-5081-3","article-title":"Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility?","volume":"23","author":"Chia","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/annonc\/mdm128","article-title":"Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)","volume":"18","author":"De Vita","year":"2007","journal-title":"Ann. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00595-009-4251-y","article-title":"Investigation of the recurrence patterns of gastric cancer following a curative resection","volume":"41","author":"Deng","year":"2011","journal-title":"Surg. Today"},{"key":"B17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1586\/era.09.179","article-title":"Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer","volume":"10","author":"Farhat","year":"2010","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/s2468-1253(19)30328-0","article-title":"The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s10120-011-0043-3","article-title":"Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer","volume":"14","author":"Hara","year":"2011","journal-title":"Gastric Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/jco.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"Jco"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","article-title":"Japanese gastric cancer treatment guidelines 2018 (5th edition)","volume":"24","year":"2020","journal-title":"Gastric Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3892\/or_00000253","article-title":"Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer","volume":"21","author":"Jung","year":"2009","journal-title":"Oncol. Rep."},{"key":"B74","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1038\/onc.2011.550","article-title":"Effects of intermittent 5-fluorouracil and low-dose cisplatin therapy on advanced and recurrent gastric cancer","volume":"32","author":"Kanetaka","year":"2012","journal-title":"Anticancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.3748\/wjg.v20.i18.5396","article-title":"Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan","volume":"20","author":"Kang","year":"2014","journal-title":"Wjg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ejca.2011.12.017","article-title":"A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer","volume":"48","author":"Kim","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s101560070007","article-title":"An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer","volume":"6","author":"Kim","year":"2000","journal-title":"J. Infect. Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10120-016-0662-9","article-title":"Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis","volume":"20","author":"Kobayashi","year":"2017","journal-title":"Gastric Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/cad.0000000000000293","article-title":"Pharmacokinetic study and clinical evaluation of a slow-release 5-fluorouracil implant in pancreatic cancer patients","volume":"27","author":"Li","year":"2016","journal-title":"Anti-cancer drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3969\/j.issn.1007-9572.2007.08.011","article-title":"Pharmacokinetic study of 5-fluorouracil based sustained release chemotherapy","author":"Li","year":"2007","journal-title":"Chin. Gen. Pract."},{"key":"B30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ijpharm.2018.07.045","article-title":"Effective sustained release of 5-FU-loaded PLGA implant for improving therapeutic index of 5-FU in colon tumor","volume":"550","author":"Li","year":"2018","journal-title":"Int. J. Pharmaceutics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12957-016-1042-y","article-title":"The patterns and timing of recurrence after curative resection for gastric cancer in China","volume":"14","author":"Liu","year":"2016","journal-title":"World J. Surg. Onc"},{"key":"B32","first-page":"694","article-title":"[Clinical observation of abdominal regional fluorouracil implants in advanced gastric cancer patients during operation]","volume":"17","author":"Liu","year":"2014","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"B33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s12094-015-1314-y","article-title":"Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction","volume":"17","author":"Mart\u00ednez-Lago","year":"2015","journal-title":"Clin. Transl Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.1016\/j.actpsy.2006.11.005","article-title":"Fluctuation in plasma 5-fluorouracil concentration during continuous 5-fluorouracil infusion for colorectal cancer","volume":"35","author":"Matsumoto","year":"2015","journal-title":"Anticancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1200\/jco.2003.04.130","article-title":"Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205)","volume":"21","author":"Ohtsu","year":"2003","journal-title":"Jco"},{"key":"B36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/00015458.2018.1453437","article-title":"Gastric cancer: factors affecting survival","volume":"119","author":"Orman","year":"2019","journal-title":"Acta chirurgica Belgica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/annonc\/mdg366","article-title":"Postoperative chemoradiotherapy for gastric cancer","volume":"14","author":"Park","year":"2003","journal-title":"Ann. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial\u2606","volume":"32","author":"Park","year":"2021","journal-title":"Ann. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40880-018-0292-1","article-title":"Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study","volume":"38","author":"Peng","year":"2018","journal-title":"Cancer Commun."},{"key":"B40","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1159\/000506509","article-title":"Gastric cancer: where are we heading?","volume":"38","author":"Petryszyn","year":"2020","journal-title":"Dig. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.2147\/ijn.s83211","article-title":"Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy","volume":"10","author":"Qu","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.ejso.2007.12.003","article-title":"Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience","volume":"34","author":"Scaringi","year":"2008","journal-title":"Eur. J. Surg. Oncol. (Ejso)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.ejso.2019.05.007","article-title":"Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: a multicenter study","volume":"45","author":"Sgarbura","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.21873\/anticanres.12945","article-title":"Intraperitoneal and systemic chemotherapy for patients with gastric cancer with peritoneal metastasis: a phase II trial","volume":"38","author":"Shinkai","year":"2018","journal-title":"Anticancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ajps.2017.04.002","article-title":"Preparation of 5-fluorouracil-loaded chitosan nanoparticles and study of the sustained release in vitro and in vivo","volume":"12","author":"Sun","year":"2017","journal-title":"Asian J. Pharm. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.12659\/msm.916475","article-title":"Recent advances in the surgical treatment of advanced gastric cancer: a review","volume":"25","author":"Tan","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"B48","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int. J. Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2174\/157016309787581084","article-title":"Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy","volume":"6","author":"van der Speeten","year":"2009","journal-title":"Cddt"},{"key":"B50","doi-asserted-by":"publisher","first-page":"Cd004064","DOI":"10.1002\/14651858.CD004064.pub4","article-title":"Chemotherapy for advanced gastric cancer","volume":"8","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40880-019-0349-9","article-title":"The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer","volume":"39","author":"Wang","year":"2019","journal-title":"Cancer Commun."},{"key":"B52","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/ctrv.2001.0232","article-title":"Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy","volume":"27","author":"Witkamp","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"497","DOI":"10.21147\/j.issn.1000-9604.2020.04.07","article-title":"Complications and risk factors for complications of implanted subcutaneous ports for intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis","volume":"32","author":"Yang","year":"2020","journal-title":"Chin. J. Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1002\/cam4.2204","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: a retrospective cooperative Central\u2010Eastern European study","volume":"8","author":"Yarema","year":"2019","journal-title":"Cancer Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12957-015-0737-9","article-title":"Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer","volume":"13","author":"Yuan","year":"2015","journal-title":"World J. Surg. Onc"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.7150\/jca.22085","article-title":"The prognostic value of age in non-metastatic gastric cancer after gastrectomy: a retrospective study in the U.S. and China","volume":"9","author":"Zhang","year":"2018","journal-title":"J. Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/jgh.13845","article-title":"Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.659258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:28:35Z","timestamp":1618295315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.659258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":56,"alternative-id":["10.3389\/fphar.2021.659258"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.659258","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"article-number":"659258"}}